Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke

G. Butera, M. R. Bini, M. Chessa, F. Bedogni, M. Onofri, M. Carminati

Research output: Contribution to journalArticle

Abstract

Background. About 50% of patients with cryptogenic stroke have a patent foramen ovale (PFO). The recurrence rate of paradoxical embolism is higher if a PFO is detected. Methods. Thirty-five patients with PFO and ≥1 thromboembolic event due to paradoxical embolism were included in the study (23 males, 12 females, mean age 47.8 ± 14 years, mean weight 75 ± 15 kg). Twenty-three patients had a transient ischemic attack whereas 12 experienced an ischemic stroke. Twenty-nine patients had one thromboembolic event, 4 patients had two thromboembolic events, and 2 patients had three thromboembolic events. The implantation procedure was performed, as previously reported, under general anesthesia, fluroscopic guidance and during transeophageal echocardiography. Results. The implantation procedure was successful in all patients. There were no complications related to the procedure. Four different devices were implanted (Amplatzer 3 patients; Cardioseal 12 patients; Starflex 12 patients, PFO Star 8 patients). The procedure time and fluoroscopic time were 50 ± 21.8 and 12.2 ± 8.3 min respectively. At transesophageal echocardiography performed after the procedure, 11 patients had a trivial shunt. None of the patients had a residual shunt at 1 month of follow-up. The mean follow-up was 12.3±8 months (median 11.0 months, range 3-37 months). In no patient did recurrence of a thromboembolic event occur during follow-up. Conclusions. Percutaneous PFO closure is a feasible and safe technique for the prevention of recurrent paradoxical embolism.

Original languageEnglish
Pages (from-to)115-118
Number of pages4
JournalItalian Heart Journal
Volume2
Issue number2
Publication statusPublished - 2001

Fingerprint

Patent Foramen Ovale
Stroke
Paradoxical Embolism
Recurrence
Transient Ischemic Attack
Transesophageal Echocardiography
General Anesthesia

Keywords

  • Catheterization
  • Embolism
  • Patent foramen ovale

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke. / Butera, G.; Bini, M. R.; Chessa, M.; Bedogni, F.; Onofri, M.; Carminati, M.

In: Italian Heart Journal, Vol. 2, No. 2, 2001, p. 115-118.

Research output: Contribution to journalArticle

@article{68f7cbc2a97e447196abbc44e44869b5,
title = "Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke",
abstract = "Background. About 50{\%} of patients with cryptogenic stroke have a patent foramen ovale (PFO). The recurrence rate of paradoxical embolism is higher if a PFO is detected. Methods. Thirty-five patients with PFO and ≥1 thromboembolic event due to paradoxical embolism were included in the study (23 males, 12 females, mean age 47.8 ± 14 years, mean weight 75 ± 15 kg). Twenty-three patients had a transient ischemic attack whereas 12 experienced an ischemic stroke. Twenty-nine patients had one thromboembolic event, 4 patients had two thromboembolic events, and 2 patients had three thromboembolic events. The implantation procedure was performed, as previously reported, under general anesthesia, fluroscopic guidance and during transeophageal echocardiography. Results. The implantation procedure was successful in all patients. There were no complications related to the procedure. Four different devices were implanted (Amplatzer 3 patients; Cardioseal 12 patients; Starflex 12 patients, PFO Star 8 patients). The procedure time and fluoroscopic time were 50 ± 21.8 and 12.2 ± 8.3 min respectively. At transesophageal echocardiography performed after the procedure, 11 patients had a trivial shunt. None of the patients had a residual shunt at 1 month of follow-up. The mean follow-up was 12.3±8 months (median 11.0 months, range 3-37 months). In no patient did recurrence of a thromboembolic event occur during follow-up. Conclusions. Percutaneous PFO closure is a feasible and safe technique for the prevention of recurrent paradoxical embolism.",
keywords = "Catheterization, Embolism, Patent foramen ovale",
author = "G. Butera and Bini, {M. R.} and M. Chessa and F. Bedogni and M. Onofri and M. Carminati",
year = "2001",
language = "English",
volume = "2",
pages = "115--118",
journal = "Italian Heart Journal",
issn = "1129-471X",
publisher = "Societa Italiana di Cardiologia",
number = "2",

}

TY - JOUR

T1 - Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke

AU - Butera, G.

AU - Bini, M. R.

AU - Chessa, M.

AU - Bedogni, F.

AU - Onofri, M.

AU - Carminati, M.

PY - 2001

Y1 - 2001

N2 - Background. About 50% of patients with cryptogenic stroke have a patent foramen ovale (PFO). The recurrence rate of paradoxical embolism is higher if a PFO is detected. Methods. Thirty-five patients with PFO and ≥1 thromboembolic event due to paradoxical embolism were included in the study (23 males, 12 females, mean age 47.8 ± 14 years, mean weight 75 ± 15 kg). Twenty-three patients had a transient ischemic attack whereas 12 experienced an ischemic stroke. Twenty-nine patients had one thromboembolic event, 4 patients had two thromboembolic events, and 2 patients had three thromboembolic events. The implantation procedure was performed, as previously reported, under general anesthesia, fluroscopic guidance and during transeophageal echocardiography. Results. The implantation procedure was successful in all patients. There were no complications related to the procedure. Four different devices were implanted (Amplatzer 3 patients; Cardioseal 12 patients; Starflex 12 patients, PFO Star 8 patients). The procedure time and fluoroscopic time were 50 ± 21.8 and 12.2 ± 8.3 min respectively. At transesophageal echocardiography performed after the procedure, 11 patients had a trivial shunt. None of the patients had a residual shunt at 1 month of follow-up. The mean follow-up was 12.3±8 months (median 11.0 months, range 3-37 months). In no patient did recurrence of a thromboembolic event occur during follow-up. Conclusions. Percutaneous PFO closure is a feasible and safe technique for the prevention of recurrent paradoxical embolism.

AB - Background. About 50% of patients with cryptogenic stroke have a patent foramen ovale (PFO). The recurrence rate of paradoxical embolism is higher if a PFO is detected. Methods. Thirty-five patients with PFO and ≥1 thromboembolic event due to paradoxical embolism were included in the study (23 males, 12 females, mean age 47.8 ± 14 years, mean weight 75 ± 15 kg). Twenty-three patients had a transient ischemic attack whereas 12 experienced an ischemic stroke. Twenty-nine patients had one thromboembolic event, 4 patients had two thromboembolic events, and 2 patients had three thromboembolic events. The implantation procedure was performed, as previously reported, under general anesthesia, fluroscopic guidance and during transeophageal echocardiography. Results. The implantation procedure was successful in all patients. There were no complications related to the procedure. Four different devices were implanted (Amplatzer 3 patients; Cardioseal 12 patients; Starflex 12 patients, PFO Star 8 patients). The procedure time and fluoroscopic time were 50 ± 21.8 and 12.2 ± 8.3 min respectively. At transesophageal echocardiography performed after the procedure, 11 patients had a trivial shunt. None of the patients had a residual shunt at 1 month of follow-up. The mean follow-up was 12.3±8 months (median 11.0 months, range 3-37 months). In no patient did recurrence of a thromboembolic event occur during follow-up. Conclusions. Percutaneous PFO closure is a feasible and safe technique for the prevention of recurrent paradoxical embolism.

KW - Catheterization

KW - Embolism

KW - Patent foramen ovale

UR - http://www.scopus.com/inward/record.url?scp=0035050996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035050996&partnerID=8YFLogxK

M3 - Article

C2 - 11256538

AN - SCOPUS:0035050996

VL - 2

SP - 115

EP - 118

JO - Italian Heart Journal

JF - Italian Heart Journal

SN - 1129-471X

IS - 2

ER -